Ultragenyx (RARE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ultragenyx (RARE) has a cash flow conversion efficiency ratio of 0.860x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-197.00 Million) by net assets ($-229.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Ultragenyx's balance sheet to measure how much of total assets are equity-financed.
Ultragenyx - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Ultragenyx's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Ultragenyx to evaluate the quality of earnings relative to operating cash generation.
Ultragenyx Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ultragenyx ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangzhong Pharmaceutical Co Ltd
SHG:600750
|
-0.001x |
|
TransMedics Group Inc
NASDAQ:TMDX
|
0.050x |
|
Enliven Therapeutics Inc.
NASDAQ:ELVN
|
-0.043x |
|
Meitu Inc
F:M5U
|
0.013x |
|
Blackstone Mortgage Trust Inc
NYSE:BXMT
|
0.050x |
|
Nantong Haixing Electronics Co Ltd
SHG:603115
|
0.000x |
|
Jizhong Energy Resources Co Ltd
SHE:000937
|
0.023x |
|
Shenglan Technology Co Ltd
SHE:300843
|
-0.013x |
Annual Cash Flow Conversion Efficiency for Ultragenyx (2011–2025)
The table below shows the annual cash flow conversion efficiency of Ultragenyx from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see Ultragenyx market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-73.00 Million | $-466.00 Million | 6.384x | +504.26% |
| 2024-12-31 | $262.30 Million | $-414.19 Million | -1.579x | +8.40% |
| 2023-12-31 | $275.41 Million | $-474.81 Million | -1.724x | -59.72% |
| 2022-12-31 | $352.49 Million | $-380.46 Million | -1.079x | -194.00% |
| 2021-12-31 | $922.56 Million | $-338.69 Million | -0.367x | -220.53% |
| 2020-12-31 | $1.15 Billion | $-132.22 Million | -0.115x | +78.32% |
| 2019-12-31 | $653.76 Million | $-345.38 Million | -0.528x | -10.71% |
| 2018-12-31 | $608.91 Million | $-290.57 Million | -0.477x | +27.92% |
| 2017-12-31 | $383.45 Million | $-253.84 Million | -0.662x | -94.92% |
| 2016-12-31 | $473.97 Million | $-160.97 Million | -0.340x | -70.20% |
| 2015-12-31 | $531.09 Million | $-105.98 Million | -0.200x | +17.32% |
| 2014-12-31 | $184.94 Million | $-44.63 Million | -0.241x | +61.24% |
| 2013-12-31 | $50.11 Million | $-31.20 Million | -0.623x | -319.98% |
| 2012-12-31 | $84.34 Million | $-12.50 Million | -0.148x | +72.91% |
| 2011-12-31 | $10.64 Million | $-5.83 Million | -0.547x | -- |
About Ultragenyx
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth fac… Read more